跳至主要内容
临床试验/CTRI/2023/02/049898
CTRI/2023/02/049898招募中3 期

A COMPARISON BETWEEN STANDARD OF CARE TREATMENT AND DAPAGLIFLOZIN ADDED TO STANDARD OF CARE TREATMENT IN LUPUS NEPHRITIS PATIENTS

DR MANISH RATHI0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • ALL NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS WITH BIOPSY PROVEN LUPUS NEPHRITIS (CLASS III,IV,V,III+V,IV+V) ARE ELIGIBLE IF THEY ARE ABOVE 18 YEARS OF AGE

排除标准

  • 1. PATIENTS HAVING PULMONARY ALVEOLAR HEMMORHAGE
  • 2. PATIENTS WITH NEUROPSYCHIATRIC SLE
  • 3. PATIENT WITH RAPIDLY PROGRESSIVE RENAL FAILURE
  • 4. PATIENTS WHO ARE ON HEMODIALYSIS
  • 5. PATIENTS WITHH eGFR LESS THAN 25 ml/min /1.73 m2
  • 6. PATIENTS WITH BASELINE CREATININE MORE THAN 3 mg/dl
  • 7. PATIENTS UNWILLING TO GIVE CONSENT

研究者

发起方
DR MANISH RATHI

相似试验

A RANDOMISED CONTROL TRIAL ON ADDING DAPAGLIFLOZIN... | 临床试验